Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New data could revive Pfizer's Mylotarg

This article was originally published in Scrip

Executive Summary

New investigator-initiated research could help revive Pfizer's acute myeloid leukaemia (AML) treatment, Mylotarg (gemtuzumab ozogamicin), following the withdrawal of the product last year.


Related Content

Pfizer's Mylotarg Likely To Get New Orphan, Biologics Exclusivities
Mylotarg Returns: US FDA Approves Pfizer's Leukemia Drug With Bonus Pediatric Indication
Pfizer's Mylotarg Rejoins AML Market At $24,600 List Price
Mylotarg, Event-Free Survival Endpoint Both Get FDA Panel Endorsement
Pfizer Hopes To Convince FDA With Event-Free Survival Data For Mylotarg


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts